Lung Cancer Trials Ask AI to find trials
CompletedPhase 1NCT04200417
Official study title

Chemoembolization for Lung Tumors

Study summary

This study is being done to determine if it is safe to perform lung chemoembolization and if the lung chemoembolization procedure can successfully deliver chemotherapy to lung tumors.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedChemoembolization and Mitomycin C

Plus 2 other study approaches.

Who it may be forLung Metastases · Endobronchial Metastases

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 16, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?4 U.S. locations

Locations may change over time.

Who runs it?Memorial Sloan Kettering Cancer Center

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Memorial Sloan Kettering Cancer Center
Interventions being studied
Procedure: Chemoembolization; Drug: Mitomycin C; Drug: Lipiodol; Drug: Embospheres
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach
Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Lung, endobronchial, pleural, or mediastinal metastases that are not responding to systemic chemotherapy, and that are not amenable to ablation, resection, or SBRT.
  • At least 18 years old.
  • ECOG performance status 0 or 1
Reasons someone may not be able to joinExclusion criteria
  • Primary lung cancer
  • \>50% of a lung is replaced with tumor
  • Oxygen saturation \<92% on room air
  • FEV1 \<60%
  • Pulmonary hypertension (diagnosed or suspected on echocardiography, CT, MRI, or direct pressure measurement)
  • Recent pulmonary embolism (within 3 months)
  • Pulmonary arteriovenous malformation
  • Active lung infection (pneumonia, empyema, or lung abscess requiring therapy within 1 month)
  • Symptomatic heart failure (dyspnea, volume overload)
  • Left bundle branch block (contraindication to pulmonary angiography)
  • Renal failure (eGFR \<30 mL/min/1.73m\^2)
  • Pregnancy
  • Breastfeeding
  • Altered mental status that would interfere with consent or follow-up
  • Platelets \< 100,000 (after transfusion, if needed)
  • INR\>2 (after transfusion, if needed)
  • Hemoglobin \<7 (after transfusion, if needed)
  • Hyperthyroidism (contraindication to lipiodol)
  • Planned radioactive iodine imaging or therapy (contraindication to lipiodol)
  • Allergy to lipiodol or mitomycin
  • Allergy to iodinated contrast that can not be treated with steroid / diphenhydramine premedication
  • Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Memoral Sloan Kettering Monmouth (Consent only)Middletown, New Jersey
  • Memorial Sloan Kettering Cancer Center @ Commack (Consent Only)Commack, New York
  • Memoral Sloan Kettering Westchester (Consent only)Harrison, New York
  • Memorial Sloan Kettering Cancer CenterNew York, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 16, 2025. Always confirm current availability with the study team.

View original record ↗